MOG and neoplasm: demonstrated that synNotch receptors, primed by recognition of a highly specific antigen such as EGFRvIII, or a CNS tissue–restricted cue like myelin oligodendrocyte glycoprotein (MOG), can transcriptionally induce a CAR targeting more homogenously expressed but less tumor-specific antigens, including EphA2 or IL13Rα2.